OncoAssure™ Prostate Cancer Gene Expression Panel
Prostate cancer is one of the most common cancers in men, particularly after the age of 65. In 2024, there were approximately 300,000 new cases in the United States, with about 1 in 8 men expected to develop the disease during their lifetime. Prognosis varies greatly depending on stage: localized prostate cancer has a nearly 100% 5-year survival rate, whereas metastatic disease has only about 32% survival, making it one of the top three causes of cancer-related death in men.
Traditional biomarkers such as total PSA remain widely used but lack sufficient sensitivity and specificity for predicting aggressive disease or recurrence following radical prostatectomy. To address this gap, OncoAssure™ developed a multigene expression panel that evaluates the activity of six genes (FOXM1, MCM3, MTUS1, TTC21B, ALAS1, and PPP2CA) associated with prostate cancer progression.
The OncoAssure™ Prostate Cancer Gene Expression Panel is a prognostic assay that integrates gene expression with clinical data to generate a risk score. This score stratifies patients recently diagnosed with early-stage prostate cancer according to their probability of 5-year biochemical recurrence. Unlike PSA testing, the OncoAssure™ panel provides more accurate risk assessment, guiding decisions about active surveillance versus definitive therapy.
- Assists in initial risk assessment for newly diagnosed early-stage prostate cancer
- Predicts the risk of 5-year biochemical recurrence after prostatectomy
- Supports decision-making for active surveillance versus aggressive treatment
- May benefit men with a family history of prostate cancer
Not applicable (results are reported as a calculated risk score)
Whole blood, EDTA. Alternative: FFPE tissue.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: 30 days
FFPE tissue are stable at room temperature for long time.
- BJUI Compass. 2024 Dec 13;6(1):e474. [PMID: 39877562]
- Eur Urol Focus. 2023 Nov;9(6):983-991. [PMID: 37105783]
- Curr Issues Mol Biol. 2022 Jan 15;44(1):360-382. [PMID: 35723406]
- Br J Cancer. 2024 Dec;131(11):1748-1761. [PMID: 39402324]